GENFIT Stock Euronext Paris
Equities
FR0004163111
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- EUR | - |
Sales 2024 * | 89.63M 95.94M | Sales 2025 * | 48.78M 52.21M | Capitalization | 161M 172M |
---|---|---|---|---|---|
Net income 2024 * | 15M 16.05M | Net income 2025 * | -21M -22.48M | EV / Sales 2024 * | 1.49 x |
Net cash position 2024 * | 27.6M 29.54M | Net cash position 2025 * | 44.9M 48.06M | EV / Sales 2025 * | 2.38 x |
P/E ratio 2024 * |
6.88
x | P/E ratio 2025 * |
24.9
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 86.72% |
Latest transcript on GENFIT
Managers | Title | Age | Since |
---|---|---|---|
Pascal Prigent
CEO | Chief Executive Officer | 56 | 18-04-30 |
Founder | 68 | 99-08-31 | |
Thomas Baetz
DFI | Director of Finance/CFO | 50 | 21-04-21 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 67 | 21-03-03 | |
Founder | 68 | 99-08-31 | |
Founder | 52 | 99-09-14 |
1st Jan change | Capi. | |
---|---|---|
+3.13% | 42.11B | |
+48.83% | 40.08B | |
+8.49% | 40B | |
-10.82% | 26.87B | |
+8.26% | 24.58B | |
-23.69% | 18.44B | |
+1.58% | 11.94B | |
+32.83% | 11.66B | |
+6.63% | 11.01B |